Page 1686 - Clinical Small Animal Internal Medicine
P. 1686
1624 Index
OMM see oral malignant melanoma primary orbital tumors 1267 osteosarcoma (OSA) 1327–1332
VetBooks.ir One Health 3–5 organophosphate toxicity 388, 808 otic cytology 1391–1392
OT see oxytocin
treatment 1268–1269
oncotic pull 349
oropharyngeal dysphagia
otitis externa 1471–1476
animal domain 4
factors driving One Health 3 473–474, 557 cutaneous adverse food reactions
human domain 3–4 Ortoloni sign 1539 1419, 1420
role for companion animal ORV see oral rabies vaccines diagnosis 1473–1474,
experts 4 OSA see osteosarcoma 1474–1475, 1475
open cardiac massage 370–371 oscillometry (OSC) 221–222 etiology/pathophysiology
OPG see osteoprotegerin osmolality 65, 440, 1070–1076 1471, 1472, 1472
opioid analgesics 410, 410 osmolarity 65 history and clinical signs 1472–1473,
opossums 892 osmole gap (OG) 440 1472–1473, 1473–1474
optic neuritis 823, 824 osmotic demyelination syndrome signalment 1471–1472
oral cavity and salivary glands (ODS) 1073 treatment and prognosis
533–546 osteoarthritis (OA) 1529–1536 1474–1476, 1476, 1476
burns 544, 545 developmental orthopedic vestibular disease 791, 792
eosinophilic granuloma diseases 1534–1544 otitis media 1477–1479
541–542, 541 diagnosis 1531, 1532 diagnosis 1477–1478, 1478
etiology/pathophysiology epidemiology 1530 etiology/pathophysiology 1477
533, 533 etiology/pathophysiology history and clinical signs 1477
foreign bodies 542 1529–1530, 1530 signalment 1477, 1477
gingivitis and periodontitis exercise and activity modification treatment and prognosis 1477,
533–536, 535 1533–1534 1478–1479, 1479
healthy oral tissues and history and clinical signs 1531 vestibular disease 791, 792
glands 533 pharmacologic/nonpharmacologic Otobius megnini 1460
immune‐mediated and agents 1534–1535 Otodectes cynotis 1471, 1474
autoimmune diseases prognosis 1536 ototoxicity 1041
542–544, 543 signalment 1530–1531 ovarian tumors 1319–1320
malignant melanoma 539 treatment: multimodal ovariohysterectomy 1318,
mechanical ventilation 400 management pyramid 1321–1324
metabolic disease 544 1531–1536, 1533 overactive bladder (OAB) 1186
odontogenic tumors and weight control 1532–1533 over‐the‐needle catheters 355
cysts 538–539 osteoblasts 1512, 1521 oxalate urolithiasis 1093, 1124–1127,
salivary gland disease 545–546 osteocalcin 1512 1126, 1137–1139
squamous cell carcinoma osteochondrosis dissecans (OCD) Oxalobacter formigenes 1126
539–541, 540 elbow dysplasia 1542–1544 oxygen extraction ratio
stomatitis 536–538, 537–538 hock joint 1544–1545 (OER) 411–412
oral malignant melanoma shoulder joint 1542 oxygen supplementation
(OMM) 1347–1348 stifle joint 1544 acute respiratory failure
oral nitrates 193 osteochondrosis (OC) 1540–1542 389–390, 390
oral rabies vaccines (ORV) 896 epidemiology 1542 cardiogenic shock 417
oral tumors 1253–126 etiology/pathophysiology critical care setting 350
diagnosis/staging 1254, 1254 1541–1542 feline bronchial asthma 300
epidemiology 1253 manifestations 1541 head trauma 756
etiology/pathophysiology 1253 osteoclasts 1512–1513, 1521 heart failure 197
history and clinical signs 1254 osteolytic bone lesions 1242 hypothermia 433
prognosis 1255–1256 osteomalacia see rickets and respiratory pattern‐based approach
signalment 1254 osteomalacia to dyspnea 290–291, 294
treatment 1254–1255 osteomyelitis 921, 923 shock 408
orbital and optic nerve tumors osteonectin 1512 surgical approaches to thoracic
1267–1269 osteopontin 1512 disease 329
diagnosis 1268, 1268 osteoporosis 1244, 1244 trauma and burns 450
history and clinical signs osteoprotegerin (OPG) 1514–1515, oxygen toxicity 401
1267–1268 1515, 1521–1522 oxytocin (OT) 40, 41
